INTRODUCTION
The word 'asthma' is derived from the Greek meaning 'panting' or 'labored breathing'. Clinically, asthma is expressed by airway obstruction that involves inflammation of the pulmonary airways and bronchial hyper-responsiveness that is usually reversible. The past decade has witnessed phenomenal increases in the incidences of asthma, asthma-related deaths, and hospitalization. The number of disability-adjusted life years (DALYs) lost due to Asthma worldwide has currently been estimated at about 15 million per year.
Worldwide, Asthma accounts for around 1% of all DALYs lost, thus reflecting the high prevalence and severity of Asthma. 2, 3 Globally, the economic costs associated with Asthma exceed those of tuberculosis and HIV/AIDS combined. 1 The economic cost of Asthma is considerable both in terms of direct medical costs (such as hospital admissions and cost of medications) and indirect medical costs (such as time lost from work and premature death).
The Global Strategy for Asthma Management and Prevention Guidelines define Asthma as a chronic inflammatory disorder of the airways associated with increased airway hyper-responsiveness, recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night/early morning. Airway inflammation produces airflow limitation through acute bronchoconstriction, chronic mucus plug formation and airway wall swelling or remodeling. 4 Although there is no cure for asthma, avoidance of triggers is a key component of improving control and preventing attacks. The most common triggers include allergens (house mites, dust), smoke (tobacco and other), air pollution etc. Treatment includes drugs that can be classified as controllers (required for maintenance treatment) and relievers (required for quick relief, rescue drugs). Relievers include drugs like short acting beta2 adrenoceptor agonists (SABA), such as salbutamol, anticholinergics like ipratropium bromide, injectable methyl xanthines and short acting corticosteroids. Controllers include mainly inhaled steroids like Fluticasone propionate, except in case of severe persistent disease, wherein oral steroids may be needed; long-acting beta2 agonists, sustained-release methyl xanthines, leukotriene receptor antagonists (Montelukast, Zafirlukast), and mast cell stabilizers (Cromolyn and Nedocromil sodium). Although these drugs offer symptomatic relief, chronic use can lead to adverse effects like exacerbation of asthma, tachycardia, and restlessness with prolonged use of bronchodilators and oropharyngeal candidiasis, obesity, fluctuating blood sugar levels, osteoporosis, cataract formation with steroids. 5, 6 Asthma is the most common chronic lower respiratory disease in childhood throughout the world and Ayurveda address it as "Tamaka Shwasa." There are five kinds of Shwasa: Kshudra, Tamaka, Chhinna, Maha and Urdhava. Tamaka Shwasa is a type of Shwasa Roga affecting the Pranavaha Srotas and characterized by prolonged expiration, wheeze, dyspnoea of exceedingly deep velocity, which is immensely injurious to life. 7 Vata moving in the reverse order pervades the channels (of vital breath), afflicts the neck and head, and stimulates Kapha (phlegm) to cause Margavarodha (blockage of respiratory passage) by producing broncho constriction. The objective of the study was to evaluate the safety and efficacy of Swasawin Asthaloc tablets when given as add-on therapy to patients suffering from mild to moderate persistent bronchial asthma.
METHODS

Study design
This was a double blind, randomized, proof of concept, controlled, prospective, interventional, Phase IV study
Ethical considerations
The study was conducted after obtaining permission from the Institutional Ethics Committee of a tertiary care hospital, Mumbai. Patients suffering from mild to moderate persistent bronchial asthma, attending the Medicine OutPatient Clinic (OPD) and fulfilling the eligibility criteria of the study were recruited into the study following written informed consent. This study was conducted as per the Indian GCP, Schedule Y, applicable government regulations and applicable ethical guidelines.
Sample size calculation
The study was planned as a pilot, comparative, Proof of Concept study. As there are no previous clinical results available with the study medication, a sample size of 60 participants (30 patients per group) was considered adequate to address the study objectives.
Study population
Patients between the age group of 18 to 70 years, suffering from mild-to-moderate persistent bronchial asthma (with recurrent symptoms like wheezing, cough which worsens on lying down, dyspnoea and chest tightness, forced expiratory volume in one second Patients suffering from other chronic lung diseases (other than asthma) such as cystic fibrosis, COPD or bronchiectasis, severe bronchial asthma (PEFR variability greater than 20%, FEV1 <20% of predicted value), with prolonged remissions (lasting more than a month), with clinically significant cardiovascular disorders, other infectious diseases, arterial hypertension, active smokers, pulmonary tuberculosis, female subjects who are pregnant, nursing or planning a pregnancy during the study, with clinically significant cardiovascular, renal, liver, neurological, neoplastic, hematological, endocrinal, infectious, dermatological, psychiatric disorders or chronic respiratory disease other than asthma and not willing to comply with protocol requirements were excluded from the study
Study conduct
Eligible patients were randomized in 1:1 ratio using computer based randomization table to one of the two study groups.
Group I received the study medication Swasawin Asthaloc tablet in a dose of 1 tablet to be taken twice daily in addition to regular anti-asthmatic medications (inhaler ± oral medications). Group II received Placebo tablets in a dose of 1 tablet to be taken twice daily only regular anti-asthmatic medications (inhaler ± oral medications). All the patients were instructed to take the medication before food with lukewarm water.
The study efficacy parameters were Spirometry, breath holding time (BHT), Ayurvedic Asthma symptom score and Asthma symptom score. Safety parameters were clinical incidence of any adverse events, hematological investigations viz. hemoglobin, total and differential leukocyte count and biochemical investigations viz. liver function tests and renal function tests.
The duration of a patient's participation in the study was of 6 months. Study assessments were conducted at monthly intervals. Study assessments included clinical history, physical examination, and assessment of the Ayurvedic symptom score designed for the study using references from Ayurvedic texts with regard to Bronchial asthma (Appendix 1). 8 This questionnaire comprises of 12 Ayurvedic symptoms which are scored using the visual analogue scale (VAS). The Asthma symptom score was assessed using parameters related to Asthmatic symptoms like coughing, wheezing, difficulty breathing, inability to perform routine activities, difficulty sleeping etc. These parameters were scored for both daytime and night-time symptoms (Appendix II). All patients were requested to refrain from consuming milk and milk based products like paneer, curds, ice-cream etc. for the entire study period. They were given patient diary cards wherein they documented the details of both milk & milk products consumed and drugs (name, dose, frequency & duration) that they had consumed for the treatment of acute attacks, if any, during the study duration.
Study medication and dosage schedule
Swasawin asthaloc tablet: Each film coated tablet weighs 600mg (Table 1 : Ingredients). 
Statistical analysis
The data is expressed as Mean ± SD (95 % Confidence Interval) for normally distributed data and Median (Range) for not normally distributed data. Kruskal Wallis/ANOVA followed by posthoc tests and Mann Whitney U test / unpaired 't' tests were used. A p value <0.05 was considered as statistically significant for all the tests.
RESULTS
75 patients were screened to participate in the study to achieve a target of 60 patients who complete the study. Of these, 15 patients were screen failures and 60 were enrolled. 50 patients completed the study, 7 patients dropped out of the study at different time points mainly due to loss in follow-up. 
Demographic distribution of patients
Majority of the patients who enrolled in the study were women (n= 45; 75%). The average age of the participants was 49.94± 10.13
Distribution of patients according to Prakriti
This distribution as shown in Figure 2 demonstrates that Asthma (Tamakashwas) is the disease which is seen predominantly in people with Kaphaprakriti ( Figure 2 ). 
Effect on the efficacy parameters
Spirometry
Both the FEV1 and PEFR values showed an improvement at the end of 6 months therapy in Group I which received the study medication as compared to Group II (Placebo group).
The results were statistically significant and are shown in Figure 3 , Figure 4 . 
Effect on Breath Holding Time (BHT)
Improvement in the breath holding time was also observed in Group I (study group) as compared to Group II (Placebo group) at the end of 6 months. The result was statistically significant at Day 180 and is shown in Figure  5 . **p <0.05 as compared to V1 using Friedman Test (Nonparametric Repeated Measures ANOVA)
Figure 5: Effect on Breath Holding Time (BHT).
Ayurvedic asthma symptom score
The Ayurvedic Asthma Symptom score was assessed with regard to the following 12 ayurvedic asthmatic symptoms using the visual analogue scale (VAS). A statistically significant improvement was observed in the following 6 symptoms as compared to the baseline scores at days 120, 150 and 180 in the study treatment group (Group I).
• Muhurmuhur Swasa (Dyspnoea), The results of the Ayurvedic Asthma Symptoms score are summarized in Table 2 .
Asthma symptom score
The Asthma day and night symptom score was assessed following review of the patient's diary card at monthly intervals. As seen from Figure 6 , Figure 7 , the study group (Group I) demonstrated an improvement in the asthmatic symptoms, both in the day and night as compared to the placebo group, though not significant statistically ( Figure 6, Figure 7 ). 
Safety evaluation
3 patients were withdrawn from the study following development of adverse events like hyperacidity (2 subjects in placebo group), constipation (1 subject in study group). No significant change was observed in the laboratory safety parameters.
DISCUSSION
Ayurveda refers to bronchial asthma as Tamaka Swasa and it is well explained in Charaka Samhita. According to Ayurveda, Asthma is a result of disturbance in the equilibrium of body humours known as Vata and Kapha, which cause obstruction in the normal course of humours (Srotorodha).
1 So a drug, which can remove the blockage, is essential in this disorder.
Bronchial asthma is a chronic inflammatory disorder and mast cell, eosinphils and T-lymphocytes plays an important role. 3 The ingredients may be collectively effective on airflow obstruction and airway hyperresponsiveness by their bronchodilatory, antiinflammatory and antihistaminic properties. 4, 5 The primary ingredient of Swasawin Asthaloc is Trikatu Powder comprising Zingiber officinale, Piper nigrum and Piper longum. These medicines have anti-inflammatory, anti-microbial, antioxidant mast cell stabilization, immunomodulatory and antiasthamatic properties. [6] [7] [8] [9] [10] [11] Another main ingredient in this preparation is Ajwain powder (Trachyspermum ammi). It contains terpine, glycosides and sterols and has been found to exert antiinflammatory effect. 12 It contains Hingu Powder (Ferula narthex) which has a potent relaxant effect on the tracheal smooth muscle which is perhaps due to muscarinic receptor blockage. 13 Kantakari Ghan (Solanum xanthocarpum) possesses anti-histaminic and antiinflammation activity.
14 Adulsa Ghan (Adhatoda vasica) is one of the ingredients which possess antispasmodic, expectorant, anti-tissue and bronchodilator effect. 15 Yashtimadhu powder (Glycyrrhiza glabra) has antiasthmatic, anti-inflammatory, anti-microbial, expectorant properties. 16, 17 Yavakshar powder (Hordeum vulgare) has antioxidant activity. 18 Kakadasingi powder (Pistacia integerrima) has anti-viral activity and reduces cough and cold. 19 Kapurkacheri Powder (Hedychium spicatum) has antibacterial, anti-pyretic and antifungal activity. 20 Dalchini Powder (Cinnamomum zeylanicum) minimizes the formation of toxic histamine and it has proven antipyretic activity. 21 Bharanghi Powder (Clerodendrum serratum) has anti-inflammatory, antihistaminic, antibacterial and anti-fungal properties. It is used in the treatment of respiratory tract infections. 22 Tulsi Swaras (Ocimum sanctum) is known to possess antiinflammatory, anti-asthmatic and immunomodulatory properties. 23 Thus, all the ingredients may help in alleviating the symptoms of Bronchial Asthma.
The efficacy parameters spirometry (both FEV1 and PEFR values), breath holding time showed an improvement at the end of 6 months therapy in Group I which received the study medication as compared to Group II (Placebo group). The improvement may be by virtue of properties of drugs of Swasawin Asthaloc tablet Thus, the drug Swasawin Asthaloc tablets can be recommended as add-on therapy in patients suffering from mild to moderate persistent Bronchial Asthma.
